FDA Rebates Biosimilar Fees And Limits Generic Fee Hike

US Agency Announces Fresh GDUFA And BsUFA Fees For FY 2022

 
• By Derrick Gingery
  
Fees up and down
Many generic and outsourcer user fees will increase in FY 2022, while biosimilar fees will remain steady or decrease • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Generics

More from Products